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Abstract 
Background Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by 
persistent inflammation and damage of joints. About 1% of the Swedish population is 
diagnosed with RA, and it is three times more common in women than in men.  
Purpose The aim of this study was to analyse a link between pain, inflammation and 
cardiovascular comorbidity in a cohort of patients with established RA. 
Method Data collected from 198 patients (women and men) diagnosed with RA were 
analysed regarding the history of cardiovascular (CV) events and current CV medications, 
pain perception and disease activity. Disease activity score, visual analogue scale, tender 
points, blood lipid profile, smoking habits, body mass index were taken into account.  
Results In the study cohort, 19% of women and 50% of men reported to have CV co-
morbidity, indicating that women had four times lower self-reported CV co-morbidity (OR 
0.23, [CI 95% 0.11-0.49]). Women had significantly lower BMI* and triglycerides* as well as 
higher HDL* than men. It was discovered that men without CVC and men with CVC were 
similar when comparing risk factors for developing CVC. On the other hand, women with 
CVC and women without CVC had significant differences in BMI*, triglycerides* and age*. 
Women experienced more pain than men did when valued tender points as they had a 
significant higher number of tender points than men*.  
Conclusions Fewer women than men had cardiovascular co-morbidity. Women with CVC do 
follow traditional pattern of risk factors for CVC whereas men without CVC and men with 
CVC were similar when comparing risk factors for developing CVC. Women and men 
perceive pain differently when value tender points. CVC do not tend to contribute to an 
increased pain in women or in men.  
Key words Rheumatoid arthritis, cardiovascular co-morbidity 
(*p<0.05)  
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Introduction 
 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent 
systemic and local inflammation in the joints, which includes synovial inflammation and 
hyperplasia, and damage of cartilage and periarticular bone destruction. Production of 
autoantibodies is an early biological marker of the disease, which may be present several years 
ahead of clinical symptoms of the joint inflammation. RA is associated with cardiovascular, 
pulmonary and skeletal disorders. The mortality rate among patients with RA is higher than 
among the general population of the same age. (1) 
About 1% of the population is diagnosed with RA and it is three times more common in 
women than in men.(2, 3) The factors predisposing to the development of RA consist of a 
combination of genetic and environmental factors in their coincidence. An example of a 
genetic factor, is the association with the human leukocyte antigen (HLA) –DRB1 locus which 
has been noticed in RA patients who are positive for rheumatoid factor, RF or anti-citrullinated 
protein antibody, ACPA. Environmental factors include smoking, dust exposure and infectious 
agents such as Epstein-Barr virus, cytomegalovirus and Escherichia coli. They have been 
associated with RA, probably due to the development of autoantibodies caused by these 
infectious agents. For some people, the risk of developing RA is increased by smoking.(1)  
 
Patient`s who is considered to have Rheumatoid arthritis but are in absence of positive 
rheumatoid factor, have seronegative Rheumatoid arthritis. The development of seronegative 
RA is probably due to hormonal factors. Early menopause in women and low testosterone 
levels in women and men has been associated with seronegative RA. Moreover, hormonal 
changes are believed to influence pathogenesis and disease progression. During the peri- and 
postmenopausal period in women, high incidence of RA is found.(4, 5)  
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Cardiovascular (CV) morbidity and mortality in RA patients is high and comparable to patients 
with diabetes mellitus.(6-8) Recent studies showed that patients with RA often die of CV 
disease, resulting in decreased life expectancy.(8-10) It has been observed that RA is associated 
with a 50-60% increased risk of CV death.(6, 9) It has also been shown that patients with RA 
have a double risk of ischemic heart disease, and that CV risk factors are seen more frequently 
in RA patients.(6, 8, 11)  
 
The high risk for cardiovascular diseases is namely mostly due to the inflammatory burden in 
RA.(12) The association between Rheumatoid arthritis and increased rates of cardiovascular 
illness is explained partly by inflammatory mediators. Cytokines and acute-phase reactants 
increase endothelial activation and potentially render atheromatous plaques unstable. 
Moreover, cytokines themselves affect muscle and adipose tissues in making them insulin-
resistant. (1) 
The typical and well-established CV risk factors include dyslipidaemia, diabetes mellitus, 
hypertension and higher body mass index (BMI).(7) On the other hand, it has also been reported 
that other risk factors such as smoking, lipid patterns and male gender have less influence in 
RA patients for developing CV co-morbidity.(13) There are also differences between women 
and men regarding development of cardiovascular morbidity. Men in general have a higher 
risk of developing CVC many years earlier than women.(14) Furthermore, a prospective 
observational study performed in Gothenburg, Sweden on 1462 randomly selected women 
aged 30-60, showed that triglycerides are one of the most important values when calculating 
risk factors for both total mortality and death from myocardial infarction, in women.(15)  
The complexity of valuing traditional risk factors in RA patients is demonstrated when value 
cholesterol and low-density lipoprotein (LDL). They have been shown to have a paradoxical 
impact on risk for CV co-morbidity since they tend to decrease on the onset of RA.(13) Even 
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tough high BMI is associated with the increased risk for CV co-morbidity in the general 
population; studies have shown that RA patients with BMI above 30 had lower mortality in 
CV disease than RA patients with lower BMI.(16, 17) On the other hand, increasing BMI and 
obesity leads to difficulties to reach disease remission in RA. Obesity is also associated with 
worse RA outcome and co-morbidities such as hypertension.(18) In summary, dyslipidaemia, 
hypertension, diabetes mellitus and decreased physical activity, all associated with CV co-
morbidity, occur more frequently in RA patients. As RA itself imply an inflammatory process 
and in combination with above stated risk factors for developing CVC, patients could have an 
increased risk of CV co-morbidity.(8) 
 
Increased risk of CV co-morbidity could be related to RA treatment. An early start of anti-
rheumatic treatment is associated with reduced CV risk.(8) The majority of RA patients are 
long-term users of the non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and 
disease-modifying drugs. It is shown that NSAIDs as well as corticosteroids are associated 
with increased risk of CV disease.(8) On the other hand, disease-modifying drugs such as 
methotrexate and biological drugs could reduce the risk of CV events including myocardial 
infarction.(6, 9) However, research regarding biological needs further randomised controlled 
trials to support findings within this field as well as to improve treatment of patients with these 
drugs. (19)  
 
RA patients describe pain as one of the most worrying difficulties in coping with their 
disease.(16) Pain affects patient’s sleep, leads to psychological distress as well as impact on 
disability. It’s believed that pain arises from joint inflammation, structural joint damage and 
central sensitization.(20) Physical disability in patients with RA leads to decreased quality of 
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life.(21) Less is known about severe pain in RA but high disease activity is associated with RA 
pain.(20)  
Furthermore, pain perception is complex, including both sensory and psychological parts. 
Pollard et al. have demonstrated this by setting up an observational study where they measured 
pain thresholds using an algometer. Their results showed that pain thresholds correlated with 
disease activity (tender joint counts), fatigue, anxiety and depression. Furthermore, RA patients 
with over eleven tender points have lower pain threshold. This is also true for patients with 
disease duration over ten years.(22) Moreover, to describe the complexity of perception of pain, 
studies have shown that men and women perceive pain differently. Women are more sensitive 
when graduating tender points than men are.(23, 24) 
 
Deeper knowledge about mechanisms of pain in RA would be of great importance for patients. 
Since the increased risk of CV events is not completely understood and the mechanism is 
complex, this study investigates a potential link between CV co-morbidity, pain and 
inflammation in RA patients visiting the Sahlgrenska University Hospital and being treated 
with methotrexate. A correlation between self-rated pain perception, tender points, and 
inflammation markers has been notice.(25) We had a hypothesis that there could be a correlation 
between CV co-morbidity, perception of pain and inflammation markers. The aim of this study 
was to analyse a link between pain, inflammation and cardiovascular comorbidity in a cohort 
of patients with established RA.  
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Material and Methods 
 
Patients 
 
Data were collected from patients who fulfilled the classification criteria of RA proposed by 
American College of Rheumatology (ACR) 1987. According to ACR 1987, for diagnose 
rheumatoid arthritis; a patient should satisfy at least 4 of 7 criteria. The criteria including; 
morning stiffness, arthritis of 3 or more joint areas, arthritis of hand joints, symmetric 
arthritis, rheumatoid nodules, serum rheumatoid factor and radiographic changes.(26) All 
patients with the diagnosis of RA, treated with methotrexate (MTX) and regularly patients at 
the Rheumatology Clinics Sahlgrenska University Hospital were eligible for the study. In 
total, 626 patients were retrieved from the list of MTX-users at the Rheumatology Clinics and 
were invited to participate in the study. One hundred ninety eight (198) patients participated 
unconstrained in the study and underwent a physical examination and filled in the self-
assessment questionnaire. Of them, 174 patients (132 females and 42 males) were included in the 
analysis and 24 patients were excluded from further analysis due to lack of complete information 
about their current medication.  
In this study, patients from Sahlgrenska University Methotrexate register were used. The 
argument for using patients treated with methotrexate is because patients who receive 
methotrexate have severe RA. Methotrexate is the most commonly used RA treatment and is 
used for patient in need of sufficient treatment. It was also an opportunity to compare patients 
who receive comparable treatment. 
Clinical assessment and Laboratory parameters 
 
The CV co-morbidity was defined by patient’s anamnesis of CV event and/or by the use of 
medical treatment as statins, acetylsalicylic acid/warfarin or hypotensives. The patient cohort 
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was stratified by gender and by CV co-morbidity. The analysis was performed with respect to 
general CV risk factors: BMI, age, smoking habits, cholesterol, high-density lipoprotein (HDL), 
low-density lipoprotein (LDL) and triglycerides levels. BMI was calculated as weight 
(kg)/length (m)2. 
To value RA inflammation, disease activity score, DAS28 was assessed. DAS28 is a commonly 
used instrument based on a cumulative index composed of erythrocyte sedimentation rate (ESR) 
(or c-reactive protein (CRP)), global patients self-assessment of health and number of swollen 
and tender joints.(2, 20, 27, 28) All patients are divided into the three commonly used groups 
depending on their individual DAS28 score.(29) The three groups are: Remission (DAS28<3.2), 
Active (DAS28 3.2 - <5.0) and High active (DAS28 5.0 -). No pooling of data has been made, 
between the three groups, in order to give the reader the complete picture of the patients RA 
inflammation status in this study.  
To value patients pain, their own perception of pain during the last week was measured by using 
visual analogue scale (VAS), results measured in mm. VAS is a visual analogue scale commonly 
used for pain perception.  
Count of tender points was measured by using the fibromyalgia diagram.(30-32) It is based on 18 
standardized points on the human body. The evaluation was performed by a physical 
examination where digital pressure was placed to these 18 standardized points on the body. The 
score were measured from 0-18. Each tender point equals one point. The 18 points are visualised 
in picture 1. 
  
 
 
Picture 1. Tender points. Open source http://commons.wikimedia.org 
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Statistics 
 
The patient cohort was stratified by gender and by CV co-morbidity. Differences between the 
groups were analysed with Mann-Whitney U test. Values are presented as median and 
percentage. Spearman's correlation coefficient (rho, ρ) was used to analyse the relationships 
between all used parameters. GraphPad Prism 6.01 was used for all statistical analyses and a 
P-value < 0.05 was considered statistically significant. 
Ethics 
 
The study is approved by the Ethical Review Board of West Göta County in Gothenburg, 
registration number 659-11, 2011-08-18. 
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Results  
Clinical characteristics of the Rheumatoid Arthritis patient cohort  
 
The study cohort consisted of 174 RA patients, 132 women and 42 men. Clinical and 
demographic characteristics of the patients are presented in Table 1a. This gender distribution 
is a 3:1 ratio (f:m),  corresponding to the prevalence of RA patients in the population world-
wide. In agreement with the inclusion criteria for the study, the patient cohort included 
subjects with established RA and the mean disease duration was above 8 years. Majority of 
the patients were of middle age, however all of them were within working age (Table 1a). 
Women and men were similar in age and in the duration and the activity of RA.  
In this study we analyse the prevalence of known CV risk factors as; high BMI, smoking, 
hypertension, high levels of triglycerides, LDL, cholesterol and low levels of HDL. The 
inflammation and activity of RA, which is considered a major risk factor predisposing to CV 
disease in this patient group, was measured by DAS28. 
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Table 1A. Clinical characteristics of the RA patient cohort 
 Women (n=132) Men (n=42) Mann-Whitney U-
test 
Age, years 57 [45-63] 59 [50-64]  
Disease duration, years 8 [5-14] 9 [6-18]  
DAS28 
Remission (<3.2) 
Active (3.2 - <5.0) 
High active (5.0 -) 
3.14 [2.06-4.11] 
68 (52%) 
51 (38%) 
13 (10%) 
2.64 [1.79-3.41] 
27 (64%) 
11(26%) 
4(10%) 
 
 
VAS-pain, mm 25 [11-48] 37 [12-57]  
Tender points, n 5 [2-9] 2 [0-5] p<0.0001 
CVC, n 
Hypertension without 
additional riskfactors 
Statins 
ASA/Warfarin 
Stroke/MI + ASA 
Hypertension+statins 
Hypertension+ASA/Warf
arin+Statins 
Hypertension+ASA/Warf
arin 
Hypertension+ASA/Warf
arin+Statins+Stroke/MI 
25 (19%) 
18  
3 
1 
1 
1 
1 
21 (50%) 
12 
 
1 
 
2 
 
 
5 
1 
OR 0.23 p=0.00016* 
 
 
 
 
 
Data are presented as median [25-75 percentile] 
* Women with CVC in relation to women without CVC compared to men with CVC in relation to men without 
CVC (The odds ratio is the ratio of the odds of the outcome in the two groups.) 
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Cardiovascular co-morbidity 
 
The CV comorbidity in this study was defined by the presence of history of major CV events 
as well as medications for hypertension, anticoagulants (warfarin or Acetylsalicylic acid) and 
statins. Only two major CV events were reported in the study – one stroke and one myocardial 
infarction. Additionally, 40/174 (23%) patients had hypotensive drugs, 10/174 (6%) used anti-
coagulants and 8/174 (5%) used statins. In this study it was found that 25 women (19%) had 
one of these CV risk factors, compared to 21 men (50%), indicating that women had 4.28 
times lower (OR 0.23, [CI 95% 0.11-0.49]) prevalence of self-reported CV co-morbidity 
compared to men. Furthermore, 15% of the women in this study used hypotensive treatment 
compared to 47.6% of the men. This indicates that it was a lower likelihood that women used 
hypotensive treatment (OR 0.19, [CI 95% 0.09-0.42]) compared to men who participated in 
this study.   
Women in this study had significantly lower BMI values compared to men (Tables 2 and 3). 
The median BMI for women was within the range of normal weight, while BMI for men was 
within the overweight group. Furthermore, women had significantly better pattern of blood fat 
values, lower levels of triglycerides compared to men and higher levels of HDL, while the 
levels of cholesterol were comparable in men and women. Low triglycerides and high HDL 
correspond to lower CV risk. Only 11.5% (20/174) of the patients reported to be current 
smokers, with a slightly higher prevalence among women compared to men (Table 1A).  
Rheumatoid arthritis activity, treatment and pain perception 
 
The participants of this study had low median disease activity of RA measured by DAS28 
(Table 1A). However, 48% of the women had active or high RA (DAS28 >3.2), while the 
majority of men (64%) were in remission.  
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The anti-rheumatic treatment may potentially be a CV risk factor. According to the inclusion 
criteria, 87% of women and 93% of men were treated with MTX at the time of enrolment in 
the study. The dose of MTX per week was similar for women and men, between 5-25 
mg/week. Remaining 10 patients have a temporary pause in their MTX treatment due to 
recent surgery or recurrent infection. In addition, 38% of the women and 50% of men were 
treated with biological drugs in combination to methotrexate. Furthermore, 11% of women 
and 17% of men used oral corticosteroids. (Table 1B)  
Table 1B. Anti-rheumatic treatment in women and men   
Drugs and no. of 
users 
Women 
No CVC 
n=107 
Women 
With CVC 
n=25 
All 
Women 
n=132 
Men 
No CVC 
n=21 
Men  
With 
CVC 
n=21 
All 
Men 
n=42 
Methotrexate 
Biological drugs 
Prednisolone 
97 (91%) 
41 (38%) 
13 (12%) 
20 (80%) 
9 (36%) 
1 (4%) 
117 (89%) 
50 (38%) 
14 (11%) 
18 (86%) 
10 (48%) 
4 (19%) 
21 (100%) 
11 (52%) 
3 (14%) 
39 (95%) 
21 (50%) 
7 (17%) 
 
Since pain is one of the major symptoms for RA patients, we investigated the perception of 
pain. In this study, women had significantly higher number of tender points (p=<0.0001) than 
men. However, when the VAS-pain was applied, no significant differences were reported 
between women and men. 
Due to the objective differences in the prevalence of CV co-morbidity and for the CV risk 
factors found between the women and men in this study, we proceeded with separate analysis 
within each gender.  
Cardiovascular co-morbidity in women 
A total of 132 women participated in the study, 107 (81.1%) of them had no CV co-morbidity 
and 25 (18.9%) reported CV co-morbidity (Table 2A). 
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Table 2A. Cardiovascular co-morbidity in RA women  
 No CVC  
(n=107)
 CVC 
(n= 25) 
Mann-Whitney 
U-test
Age, years 55 [43-63] 60 [56-65] p=0.004 
Disease duration, years  7 [4-12] 8 [6-19]  
BMI, kg/m2 24 [21.7-26.6] 27.2 [25.0-29.8] p=0.0003 
Cholesterol, mmol/L 5.4 [4.5-5.9] 5.5 [4.8-6.2]  
Triglycerides, mmol/L 0.86 [0.66-1.10] 1.2 [0.75-1.70] p=0.002 
HDL, mmol/L 
LDL, mmol/L 
1.8 [1.5-2.1] 
3.2 [2.5-3.8] 
1.6 [1.4-2.1] 
3.4 [2.8-3.95] 
 
Current smokers, n (%) 18 (17%) 2 (8%)  
DAS28 
Remission (<3.2) 
Active (3.2 - <5.0) 
High active (5.0 -) 
2.97 [2.03-4.03] 
58 (54%) 
40 (37%) 
9 (8%) 
3.47 [2.81-4.62] 
10 (40%) 
11 (44%) 
4 (16%) 
 
VAS-pain, mm 25 [11-48] 26 [10-48]  
Tender points, n 5 [2-9] 6 [3-10]  
Data are presented as median [25-75 percentile] 
In this study, women without CVC were significantly younger than women with CVC 
(p=0.004), which is in agreement with known increase in CVC with age. The groups were 
similar in the duration of RA disease but women with CVC tended to have higher disease 
activity.  
Cardiovascular co-morbidity in RA women 
 
As seen in table 2A, women without CVC had lower BMI as well as lower triglycerides than 
women with CVC. Both of these markers are associated with the increased risk of developing 
CVD. However, no significant differences were found in these groups of women when 
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comparing the blood levels of cholesterol, HDL and LDL. A correlation was found in women 
without CVC between cholesterol and HDL (ρ=0.27, p=0.015) as well as between cholesterol 
and disease duration (ρ=0.29, p=0.01). No such correlations were found in women with CVC. 
There were no significant differences when comparing smoking habits. (Table 2A) 
Rheumatoid arthritis activity, treatment and pain perception in RA women 
 
In this study, 45% of women without CVC had active or high active RA measured by DAS28 
above 3.2, in contrast to 60% of the women with CVC. Furthermore, there was a tendency to 
lower DAS28 among women without CVC as they had a median value of 2.97 and women 
with CVC had a median value of 3.47. 
In agreement with the inclusion criteria, most women used MTX, as a monotherapy or in 
combination with biological drugs (91% of the women without CVC compared to 80% of the 
women with CVC). Oral corticosteroids were used by 12% of women without CVC and in 
4% of women with CVC. (Table 1B) 
The two groups reported similar pain perception; no significant difference was found when 
comparing VAS or the number of Tender points. Since RA activity may influence the 
perception of pain, we analysed correlation between DAS28 and VAS and DAS28 and TP. A 
correlation was found between DAS28 and VAS (ρ=0.35, p=0.002) as well as between 
DAS28 and tender points (ρ=0.45, p=<0.0001) in women without CVC. However, this link 
was not seen in women with CVC. To conclude, in women without CVC, increasing DAS28 
correlate with increasing valued perception of pain, when using VAS-scale and tender-points. 
Table 2B depict increasing VAS along with increasing DAS28, in women without CVC.    
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Table 2B. Correlation of Disease activity and VAS in RA women  
  CVC No CVC CVC No CVC CVC No CVC 
DAS28 <3.2 <3.2 3.21 – 4.99 3.21 – 4.99 >5 >5 
 Remisson Active High active 
VAS median 11.5 17.5 33 31.5 25.5 64 
0-15, n 6 26 3 8 1 1 
16-46, n 3 22 4 21 2 2 
47-100, n 1 10 4 11 1 6 
 
Cardiovascular co-morbidity in men 
 
Within this study a total number of 42 male participants were included; 21 of them had CVC 
and 21 did not. The comparison between the groups of men without CVC and men with CVC 
demonstrated a significant difference in age. Men without CVC were in average twelve years 
younger than men with CVC. Men without CVC were middle aged but men with CVC were 
close to the age of retirement. The groups were similar in the duration of RA disease.  
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Table 3A. Cardiovascular co-morbidity in RA men 
 No CVC 
n=21
CVC 
n=21
Mann-Whitney 
U-test 
Age, years 51 [41-62] 63 [58-65] p=0.0089 
Disease duration, years 8 [4-15] 9 [6-22]  
BMI, kg/m2 27 [23.3-30.9] 28.4 [25.5-29.3]  
Cholesterol, mmol/L 5.3 [4.3-6.1] 5.2 [4.3-5.9]  
Triglycerides, mmol/L 0.99 [0.76-1.60] 1.10 [0.87-2.20]  
HDL, mmol/L 
LDL, mmol/L 
1.5 [1.2-1.8] 
3.5 [2.7-4.2] 
1.3 [0.98-1.55] 
3.2 [2.45-4.15] 
 
Current smokers, n (%) 2 (10%) 3 (14%)  
DAS28 
Remission (<3.2) 
Active (3.2 - <5.0) 
High active (5.0 -) 
2.67 [1.91-3.34] 
14 (67%) 
7 (33.3%) 
0 
2.42 [1.73-4.44] 
13 (62%) 
4 (19%) 
4 (19%) 
 
VAS-pain, mm 35 [10-61] 37 [12-51]  
Tender points, n  1 [0-5] 2 [1-5]  
Data are presented as median [25-75 percentile] 
Cardiovascular co-morbidity in RA men  
 
In this study, men without CVC and men with CVC were similar with respect to the 
traditional CV risk factors, BMI, smoking habits and the pattern of blood fat measured by the 
levels of cholesterol and triglycerides (Table 3A). Correlations were found between 
cholesterol and HDL (ρ=0.55, p=0.015) as well as between cholesterol and disease duration 
(ρ=0.46, p=0.049) in men without CVC. No correlations were found between these variables 
in men with CVC.  
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Rheumatoid arthritis activity, treatment and pain perception in RA men 
 
The disease activity of RA, measured by the cumulative index DAS28, indicated that most of 
the men in this study had a remission of their RA disease. No significant difference in DAS28 
was found between men without CVC and men with CVC (Table 3A). None of the men 
without CVC had high active RA compared to 19% of men with CVC.  
RA treatment was similar between the groups, regardless of CVC, 86% of men without CVC 
and 100% of the men with CVC were treated with MTX. Half of the RA men were treated 
with biological drugs, 48% of the men without CVC and 52% of the men with CVC. 
Furthermore, less than 1/5 of the men used oral corticosteroids. (Table 1B) 
In this study, the perception of pain according to VAS and to the number of tender points was 
similar between the men without CVC and the men with CVC (Table 3A). However, when 
dividing RA patients in to three groups by their disease activity, the patients reported higher 
pain perception (VAS) in correlation with higher DAS28 (Table 3B). Furthermore, men with 
CVC had a clear correlation between DAS28 and VAS (ρ=0.48, p=0.038), and between 
DAS28 and tender points (ρ=0.55, p=0.014). No such correlations were found within the 
group of men without CVC.  
Table 3B. Correlation between disease activity and VAS in RA men 
 CVC No CVC CVC No CVC CVC No CVC 
DAS28 <3.2 <3.2 3.21 – 4.99 3.21 – 4.99 >5 >5 
 Remission Active High active 
VAS median 16 21 38.5 46 55 0 
0-15, n 6 7 0 2 0 0 
16-46, n 4 2 4 2 2 0 
47-100, n 3 5 0 3 2 0 
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Discussion   
 
Cardiovascular co-morbidity 
 
A large amount of all RA patients have CV comorbidity.(11) Intriguingly, a clearly significant 
difference was found in this study, when comparing the number of women and men with 
CVC. 19% of women and 50% of men reported to have CV co-morbidity, indicating that 
women had four times lower self-reported CV co-morbidity. The reason for this difference 
between women and men could be that men tend to develop CV diseases 10-20 years earlier 
than women do.(14) This could indicate that this difference, in this study cohort, is caused by 
gender.  
The typical CV risk factors include dyslipidaemia, diabetes mellitus, hypertension and higher 
body mass index (BMI).(7) Women with CVC do follow some of this traditional pattern of risk 
factors for CVC as they had higher: triglycerides, BMI and age than women without CVC. In 
line with other findings, in women triglycerides are one of the most important values when 
calculating risk factors for both total mortality and death from myocardial infarction.(15)  
A tendency to higher inflammatory parameters was seen in women with CVC who has higher 
BMI, triglycerides and age than women without CVC. Studies have shown that increasing 
BMI leads to difficulties to reach disease remission in RA.(18) 
Men in this study had more risk factors for developing CV co-morbidity because of their high 
BMI, high triglycerides as well as low HDL compared to women. In line with other findings, 
men in this study had many risk factors for developing cardiovascular diseases.(8) Moreover, 
men without CVC and men with CVC were similar with respect to BMI, smoking habits, and 
the pattern of blood fat measured by the levels of cholesterol and triglycerides, indicating 
similarity in risk for developing CVD. One can hypothesize that men without CVC in this 
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study could be underdiagnosed since they are comparable with men with CVC. When 
comparing with the Swedish population in general, within the group of 55-64 years, 20.3% of 
the women have hypertension and 23.2% of the men.(33) In this study, 15% of the women 
reported the use of medicaments for hypertension versus as much as 47.6% of the men. Men 
in this study have more developed CVC than the male population in average as they have 
higher incidence of hypertension. One could speculate if their RA could have affected the 
development of CVC. Men in this study have higher incidence of use of medicament treating 
hypertension than men in general, in this age category, Studies have shown that RA patients 
have a 50% increased risk of mortality due to CVC.(34, 35) 
Rheumatoid arthritis activity and treatment  
 
To participate in the study one had to be treated with MTX. That explains why so many of the 
participants have reported their use of this medicament. Due to the fact that some of the 
participants had a temporary pause in their MTX treatment, not 100% used this medicament at 
the moment of investigation.  
There were no significant differences when comparing use of medicaments between women 
and men. However, 38% of the women without CVC and 36% of women with CVC used 
biological drugs, compared to approximately 50% within men as a group. Men tend to use 
both biological drugs and corticosteroids more frequently then women did.  
The development of CVC in Rheumatoid Arthritis is caused by an underlying inflammation, 
the use of RA medicament as well as traditional cardiovascular risk factors.(8) It is believed 
that Methotrexate and biologicals could reduce the risk of CVC while corticosteroids have 
harmful effect on blood-lipids as well as blood pressure.(8) Men in this study did use both 
more biological drugs and corticoids then women. As much of 50% of men in this study had 
CVC but the majority of men (64%) were in remission in their RA. Further studies in how RA 
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treatment affects patients in their development of both CVC and RA would be interesting. 
Moreover, a research investigating when patients started with their anti-rheumatic treatment 
would be of great interest since early start of anti-rheumatic treatment is associated with 
reduced CV risk.(8) 
Pain perception 
 
High disease activity is believed to be associated with RA pain.(20) In this study this is true for 
women without CVC and men with CVC as increasing DAS28 correlate with increasing 
valued perception of pain, when using VAS-scale and tender-points. Increasing VAS along 
with increasing DAS28 is true for all patients except for women with CVC with high active 
RA. However, the group of women with CVC and high active RA consisted of only four 
participants. None of the men appertained to the group of men without CVC and high active 
RA. Further research regarding pain perception and disease activity with additional patients 
would be of great interest to get manifest conclusions.   
When comparing participants with and without CVC, both women and men in both groups 
perceived pain very similar. No differences were found when comparing VAS or Tender 
points between these groups. This might indicate that cardiovascular diseases do not effect the 
sensation of pain. However, women tend to value their pain much higher than men did 
concerning palpation of certain areas of the body, tender points (TP). When comparing tender 
points, men had significant lower amount of tender points than women (p=<0.0001). In line 
with other findings, it has been shown that women are more sensitive when graduating tender 
points then men are and that men and women perceive pain differently.(23, 24)  
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Conclusion 
 
In this study, it has been found that fewer women than men reported cardiovascular co-
morbidity. These findings reflect the general population since women tend to develop CVC 
later than men do.  
Established CV risk factors are for example dyslipidaemia, hypertension, high BMI and high 
age. Women in this study who reported CVC do follow these traditional patterns of risk 
factors. However, even though half of the men reported CVC, men without CVC and men 
with CVC were similar when comparing risk factors for developing CVC. No significant 
distinctions were found when comparing neither risk factors nor inflammation parameters 
between men without CVC and men with CVC.  
In line with other findings, women and men valued their pain very differently when graduate 
tender points. However, no differences were found when comparing VAS-pain. Furthermore, 
similar pain perception was reported from both women and men without CVC as well as 
women and men with CVC. To conclude, CVC was not associated with increased pain 
perception in RA patients.  
Methodological considerations  
This is an observational study. Observational studies is used for investigate possible 
relationships between exposure and outcomes. Moreover, this cross-sectional study has 
analysed the situation at present and it is not prospective. No control group was used in this 
study. This observational study was instead concentrated on finding differences or similarities 
within RA patients who receive comparable treatment. As diabetes mellitus occur more 
frequently in patients with RA and is also a well-established cardiovascular risk factor, one 
can argue for include diabetes mellitus as a definition of CVC.(36) On the other hand, 
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cardiovascular morbidity and mortality in RA patients is high and comparable to patients with 
diabetes mellitus.(6-8) Therefore, it could have been an opportunity to use patients with diabetes 
mellitus as a control group.  
In this study, patients from the Methotrexate register were used. They participated voluntary 
and filled in a self-assessment questionnaire, underwent a physical examination and left a 
laboratory test with blood sampling. All patients fulfilled the classification criteria of RA 
proposed by ACR 1987.(26) 1987 ACR criteria are believed to have higher specificity especially 
in patients aged > 60 years in order to diagnose RA, than the newer 2010 ACR/EULAR criteria. 
Moreover, 1987 ACR criteria are suggested to predict a more erosive disease whereas the 2010 
criteria classify more patients with RA and at an earlier phase of the disease.(37, 38)  
 
The argument for using patients treated with methotrexate is because this medicament is the 
most commonly used RA treatment and constitute the basis in RA therapy. Moreover, patients 
who receive methotrexate have severe RA and are in need of sufficient treatment.     
Information concerning patient’s medicaments came from the patients and was not double-
checked. This could lead to inaccurate information as patients could forget or misunderstand 
questions.  However, unfilled questionnaires with ambiguous information was not included in 
the study.  
Furthermore, blood samples were taken at only one occasion and no considerations were 
taken to temporary infections or variables that could have intrude the data.  
Since the number of patients included in this study is somewhat limited, more studies 
including larger numbers of patients have to be performed and the results in this study need to 
be verified by further studies. Moreover, especially the number of men was limited and the 
conclusions from the study are therefore more relevant for women.   
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Abbreviation list 
 
BMI  Body Mass Index 
CRP C-reactive protein 
CVC Cardiovascular co-morbidity 
DAS28  Disease Activity Score 
ESR  Erythrocyte sedimentation rate 
HDL High-density lipoprotein  
LDL Low-density lipoprotein 
NSAIDs  Non-steriodal anti-inflammatory drugs  
RA Rheumatoid arthritis  
TP Tender Points  
VAS Visual analogue scale 
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Populärvetenskaplig sammanfattning  
 
Ledgångsreumatism (eg. Reumatoid artrit) är en kronisk autoimmun sjukdom som cirka en 
procent av Sveriges befolkning har och sjukdomen är ungefär tre gånger så vanlig hos kvinnor 
som hos män. Inflammationen som kommer av sjukdomen leder till värk, smärta och stelhet i 
leder men även andra organ kan påverkas. Påverkan på lederna sker symmetriskt i kroppen 
och det är alltid flera leder som påverkas.  
Det har visat sig att patienter med ledgångsreumatism lider av högre risk att drabbas av hjärt- 
kärlsjukdomar (jämförbart med risken hos dem som lider av sockersjuka (diabetes mellitus)). 
Kända riskfaktorer till hjärt-kärlsjukdom hos patienter med ledgångsreumatism är 
blodfettrubbning, sockersjuka, högt blodtryck samt ökat kroppsmasseindex (Body Mass 
Index, BMI). Även behandlingseffekter skulle kunna vara en förklaring till den ökade risken 
för hjärt-kärlsjukdom med detta är ännu inte helt klarlagt.  
En studie som undersöker ovanstående samband ytterligare är därför av stor betydelse då det 
skulle kunna leda till att bättre förebygga riskfaktorer för hjärt-kärlsjukdom samt ett bättre 
omhändertagande av dessa patienter. 
Denna studie har analyserat sambanden mellan smärta, inflammation och hjärt-kärlsjukdomar 
in en grupp av patienter med diagnosticerad ledgångsreumatism. Data har insamlats från 
Sahlgrenska Universitetssjukhusets Metotrexat register från 198 kvinnor och män med 
diagnosen ledgångsreumatism. Dessa data har undersökts bland annat med avseende på 
inflammationsmarkörer, självupplevd smärta, svullna och smärtande leder, historia av hjärt-
kärlsjukdom, blodfetter, rökning samt kroppsmasseindex. 
Resultatet i studien visar att 19 % av kvinnorna lider av eller upplevt någon hjärt-kärlsjukdom 
i jämförelse med 50 % av männen. Av de riskfaktorer som nämns ovan syns att män generellt 
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lider av större blodfettsrubbning än kvinnor och att de också har högre kroppsmasseindex. 
Vad gäller aktiviteten av sjukdomen visade studien att nästan 50 % av kvinnorna led av aktiv 
eller mycket aktiv ledgångsreumatism i jämförelse med männen där 64 % hade en sjukdom 
som stället var i avtagande fas, remission. Kvinnor uppgav också i större utsträckning än män 
att de hade mer smärta gällande ömmande punkter på kroppen. 
Denna studie visar att kvinnor med hjärt-kärlsjukdom har signifikant högre 
kroppsmasseindex, är äldre och har högre triglycerider (blodfetter) än kvinnor utan hjärt-
kärlsjukdom. Detta är faktorer av betydelse för utvecklingen av hjärt-kärlsjukdom. Vidare har 
60 % av kvinnorna med hjärt-kärlsjukdom en aktiv eller mycket aktiv ledgångsreumatism i 
jämförelse med 45 % av kvinnorna utan hjärt-kärlsjukdom. 50% av männen hade redan 
utvecklat hjärt-kärlsjukdom även fast inga nämnvärda skillnader fanns mellan män utan hjärt-
kärlsjukdom och män med hjärt-kärlsjukdom. 
Då patienterna som deltog i denna studie var en del av Sahlgrenskas Metotrexat register 
behandlades de allra flesta med denna medicinering. Dock fanns skillnader mellan män och 
kvinnor gällande behandlingen med nyare biologiska läkemedel och kortison. 50% av männen 
behandlades med biologiska läkemdel till skillnad mot kvinnor där 38% hade dessa 
läkemedel. 17% av männen behandlades med kortison i jämförelse med 11% av kvinnorna.  
Sammanfattningsvis visar således studien att kvinnor generellt har en mer aktiv sjukdom än 
män samt att kvinnor som har en hjärt-kärlsjukdom i större utsträckning också har en mer 
aktiv ledgångsreumatism. Större andel män än kvinnor led av hjärt-kärlsjukdom trots adekvat 
behandling och låg aktivitet i sin ledgångsreumatism. Detta kan antas bero på att män 
generellt sett utvecklar hjärt-kärlsjukdom flera år tidigare än kvinnor.   
För att bringa ytterligare klarhet i varför dessa samband föreligger och vad vi kan göra åt dem 
behövs ytterligare forskning inom området. Detta är mycket viktigt för att öka förståelsen och 
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kunskapen kring ledgångsreumatism då det leder till ett bättre omhändertagande av 
patienterna samt att nya behandlingsriktlinjer kan introduceras.  Genom forskning finns 
förutsättningar för att patienter som lider av ledgångsreumatism med eller utan hjärt-
kärlsjukdom kommer ha få ett allt friskare och välmående liv.  
 
 
